Akero Therapeutics MASH Treatment Trial Data: Stock Up 21%

Akero Therapeutics Reports Positive Preliminary Results from Phase 2b Study on Efruxifermin

Key Points:
– Akero Therapeutics saw a 21% increase in its shares following the release of positive preliminary results.
– Results are from a Phase 2b study evaluating the efficacy and safety of efruxifermin.
– The study focused on patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (NASH) and fibrosis stage 2 or 3.
– The study achieved its primary endpoint of 1-stage improvement in fibrosis with no worsening of NASH after 24 weeks of treatment for both dose groups.